Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARVN Arvinas Holding Company LLC

Market Closed 11-13 16:00:00 EST

6.82

-0.05

-0.73%

盘后6.82

+0.000.00%

19:30 EST

High6.90	Low6.62	Vol879.36K
Open6.88	D1 Closing6.87	Amplitude4.15%
Mkt Cap445.93M	Tradable Cap386.49M	Total Shares65.39M
T/O5.97M	T/O Rate1.55%	Tradable Shares56.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":6.82,"timestamp":1794603600000,"preClose":6.87,"halted":0,"volume":879356,"hourTrading":{"tag":"盘后","latestPrice":6.82,"preClose":6.82,"latestTime":"19:30 EST","volume":32054,"amount":218608.28,"timestamp":1794616202135,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007278020378457034,"floatShares":56669600,"shares":65386200,"eps":-0.152308,"marketStatus":"Market Closed","change":-0.05,"latestTime":"11-13 16:00:00 EST","open":6.88,"high":6.9,"low":6.615,"amount":5969013.128572,"amplitude":0.041485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.152308,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":6.87,"preHourTrading":{"tag":"盘前","latestPrice":6.96,"preClose":6.87,"latestTime":"09:11 EST","volume":1394,"amount":9390.899858,"timestamp":1794579085740,"change":0.09,"changeRate":0.0131,"amplitude":0.160116},"postHourTrading":{"tag":"盘后","latestPrice":6.82,"preClose":6.82,"latestTime":"19:30 EST","volume":32054,"amount":218608.28,"timestamp":1794616202135,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9538758322977605,"impliedVol":1.023,"impliedVolPercentile":0.9283},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"2681861845","title":"BofA Securities Adjusts Arvinas Price Target to $15 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2681861845","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681861845?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:09","pubTimestamp":1793970585,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) has an average rating of overweight and mean price target of $13.93, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681021644","title":"Growth Investors: Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681021644","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681021644?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:38","pubTimestamp":1793878687,"startTime":"0","endTime":"0","summary":"SSimply Wall StNovember 5, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arvn/arvinas/news/growth-investors-industry-analysts-just-upgraded-their-arvin","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arvn/arvinas/news/growth-investors-industry-analysts-just-upgraded-their-arvin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","ARVN",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681101718","title":"AI-Driven Drug Discovery at Arvinas: Operational Risks, Regulatory Pressures, and Financial Fallout","url":"https://stock-news.laohu8.com/highlight/detail?id=2681101718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681101718?lang=en_us&edition=fundamental","pubTime":"2026-11-05 14:01","pubTimestamp":1793858486,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company (ARVN) has disclosed a new risk, in the Technology category. Arvinas Holding Company’s growing reliance on AI and machine l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ai-driven-drug-discovery-at-arvinas-operational-risks-regulatory-pressures-and-financial-fallout?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ai-driven-drug-discovery-at-arvinas-operational-risks-regulatory-pressures-and-financial-fallout?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CHAT","VTHR","AGIX","ARVN","ARTY","QTOC","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681106742","title":"Arvinas Plans Preliminary Phase 1 Data Presentation for Lymphoma Drug ARV-393 at ASH 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2681106742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681106742?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:09","pubTimestamp":1793826576,"startTime":"0","endTime":"0","summary":"Arvinas Plans Preliminary Phase 1 Data Presentation for Lymphoma Drug ARV-393 at ASH 2026Arvinas will present preliminary Phase 1 results for ARV-393 (zaloblideg) at the American Society of Hematology","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL3LPhl8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014013.SGD","LU2095319765.USD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","SG9999014039.USD","ARVN","BCDF","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU2210150020.SGD","BK4007","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680805612","title":"Viridian Posts First Lumvoa Revenue but Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2680805612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680805612?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:27","pubTimestamp":1793795254,"startTime":"0","endTime":"0","summary":"Viridian posts first Lumvoa revenue but net loss widensOverviewU.S. biotech firm reported first net product revenue from Lumvoa after TED launch in Q3Q3 net loss widened to $101.2 mln from $34.6 mln a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","BK4505","BK4139","BK4611","LU1861559042.SGD","ARVN","BK4556","BK4007","VRDN","LU1861558580.USD","BEAM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680035992","title":"US Research Roundup-Amgen, Carmax, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2680035992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680035992?lang=en_us&edition=fundamental","pubTime":"2026-11-04 17:01","pubTimestamp":1793782892,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Amgen, Carmax, PfizerNov 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amgen, Carmax and Pfizer, on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL3N46L0W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMD","KMX","ADUS","CNM","XYZ","CBLL","UPGR","AME","APO","BEAM","ADM","CNK","ASBH","BRCC","ADBE","PRVT","AESI","EGGY","XNTK","ADTN","ANET","ADBG","AMRX","BE","AXSM","ATRC","SMOG","BKNG","ALKS","CCB","BKNU","CALX","CMCO","PBE","AN","BALL","SMHX","CYH","AMDU","CORT","APTV","ARVN","TBXU","AMGN","ALAB","BR","CWH","AMWL","CE","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680708303","title":"Arvinas - May Offer Securities up to $400 Mln Aggregate Offering Price - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2680708303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680708303?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:38","pubTimestamp":1793741907,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nFWN46K2EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680763047","title":"Arvinas Price Target Cut to $13.00/Share from $18.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2680763047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680763047?lang=en_us&edition=fundamental","pubTime":"2026-11-04 01:39","pubTimestamp":1793727540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680778173","title":"Arvinas, Inc. : H.c. Wainwright Cuts Target Price to $13 from $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2680778173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680778173?lang=en_us&edition=fundamental","pubTime":"2026-11-03 23:38","pubTimestamp":1793720310,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nAZN4TSOGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680726503","title":"Arvinas Presents Preclinical Data on BCL6 Degrader ARV-393 in Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2680726503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680726503?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:24","pubTimestamp":1793708642,"startTime":"0","endTime":"0","summary":"Arvinas presents preclinical data on BCL6 degrader ARV-393 in lymphomaArvinas’ VEPPANU (vepdegestrant) received FDA approval on May 1, 2026, becoming the first approved PROTAC protein degrader.Rigel l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL8N3mtN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680472546","title":"Arvinas Q3 Revenue Drops Sharply on Lower Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2680472546","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680472546?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:11","pubTimestamp":1793707884,"startTime":"0","endTime":"0","summary":"Arvinas Q3 revenue drops sharply on lower milestone paymentsOverviewUS biotech firm's Q3 revenue fell sharply yr/yr due to lower milestone and collaboration paymentsCompany posted a wider net loss in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0823416689.USD","BK4611","LU1861558580.USD","LU2324357040.USD","LU2065170008.USD","QURE","LU2065171402.SGD","BK4556","ARVN","LU0320765992.SGD","LU2065171311.SGD","LU2065169927.USD","NBIX","BK4588","CRSP","ARKG","LU1861559042.SGD","LU0109394709.USD","BK4585","LU0889565916.HKD","BK4139","LU0154245756.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680725671","title":"Arvinas Q3 Net Loss Widens 54% to $53.9 Million; Q3 Revenue Drops 99% to $500,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2680725671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680725671?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:07","pubTimestamp":1793707658,"startTime":"0","endTime":"0","summary":"Arvinas Q3 net loss widens 54% to $53.9 million; Q3 revenue drops 99% to $500,000Arvinas’ third-quarter 2026 net loss widened 54% year over year to $53.9 million.Revenue dropped 99% year over year to ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL8yv7bQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","BK4007","ARVN","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4588","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BCDF","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680521725","title":"Arvinas Q3 EPS $(0.82) Beats $(0.83) Estimate, Sales $500.000K May Not Be Comparable To $22.490M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680521725","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680521725?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:05","pubTimestamp":1793707509,"startTime":"0","endTime":"0","summary":"Arvinas Q3 EPS $(0.82) Beats $(0.83) Estimate, Sales $500.000K May Not Be Comparable To $22.490M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/ARVN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680725340","title":"Arvinas - Cash and Equivalents Sufficient to Fund Operations into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2680725340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680725340?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:00","pubTimestamp":1793707207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nPLX2ZP0Q9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680231227","title":"Arvinas Q3 Revenue USD 500 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2680231227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680231227?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:00","pubTimestamp":1793707207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nPLX2ZP0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680104697","title":"US Research Roundup-Bright Minds Biosciences, Marvell Technology, Oracle Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2680104697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680104697?lang=en_us&edition=fundamental","pubTime":"2026-11-03 15:34","pubTimestamp":1793691243,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle CorporationNov 3 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed compani","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL3N46K0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLDR","ARTY","ASB","AEHR","BILT","CBNA","AVBH","PTH","AXSM","CHH","ASMB","EINC","CHTR","PRVT","CHD","ACIW","AAPL","AEP","BLZE","CBOE","RCEL","AIS","ARES","CENX","CBT","LNGX","BKNG","AB","ARVN","AEIS","BWXT","CG","ATEC","BXMT","LNT","AN","PINE","WUGI","LAZR","LNG","MRVL","APPN","BBWI","AJG","DRUG","CE","VPU","BMRN","AMP","ABNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678179824","title":"Arvinas to Report Third-Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2678179824","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678179824?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:09","pubTimestamp":1793099368,"startTime":"0","endTime":"0","summary":"Arvinas to Report Third-Quarter Financial ResultsArvinas will review third-quarter 2026 results and provide a corporate update via live webcast November 3, 2026, at 8:00 a.m. ET.Disclaimer:This news b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDLbBYGk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","ARVN","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678178810","title":"What Arvinas Holders Got Wrong Before The Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2678178810","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678178810?lang=en_us&edition=fundamental","pubTime":"2026-10-27 17:15","pubTimestamp":1793092501,"startTime":"0","endTime":"0","summary":"When Arvinas reported Q2 2026 results showing revenue of US$249.7 million and net income of US$169.4 million, with net margin shifting from a heavy loss a year earlier to 67.8%, the headline story looked transformed. For Arvinas shareholders, the loss from the start of the year was 36.3%, including dividends. If you had been weighing a position back on 1 January, how should this kind of swing in reported performance have shaped your expectations?\nNarratives are how investors here put a case...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arvn/arvinas/news/what-arvinas-holders-got-wrong-before-the-slide","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arvn/arvinas/news/what-arvinas-holders-got-wrong-before-the-slide","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675300224","title":"Big Pharma is Pouring Billions into a New Class of 'Protein Degrader' Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2675300224","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675300224?lang=en_us&edition=fundamental","pubTime":"2026-10-15 17:30","pubTimestamp":1792056600,"startTime":"0","endTime":"0","summary":"After Lisa Moore's cancer treatments stopped working, the 64-year-old enrolled in a study to try out a new type of drug, one that is programmed to go after disease in cells in a novel way.Ten months l","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0061475181.USD","LU1236620834.HKD","LU0432979614.USD","BK4585","RIGL","BK4007","IE00B2B36J28.USD","ONC","LU1883839398.USD","BK4534","LU0321505868.SGD","BK4526","LU1236620750.USD","ARVN","LU1670710588.SGD","LU2596442595.SGD","NRIX","LU2133065610.SGD","LU0114720955.EUR","LU1585245621.USD","LU1670710661.SGD","LU1868836591.USD","BK4588","IHE","BMY","BK4581","BK4559","IE00BFXG1179.USD","LU1868837300.USD","LU0306807586.USD","LU1291159041.SGD","LU1032466523.USD","LU1868837136.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1261432733.SGD","KYMR","FTXH","LU0267386448.USD","LU1093756168.USD","LU0225771236.USD","LU2360032135.SGD","LU0096364046.USD","LU0306806265.USD","LU2125154935.USD","LU1718418525.SGD","LU1670711123.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673368097","title":"Arvinas: Findings Support Evaluation of Arv-102 as a Therapeutic Approach for Neurodegenerative Diseases Associated with Lrrk2 Dysregulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673368097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673368097?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:03","pubTimestamp":1791370987,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T0YF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":0.064},{"period":"1month","weight":0},{"period":"3month","weight":-0.2397},{"period":"6month","weight":-0.2489},{"period":"1year","weight":-0.3261},{"period":"ytd","weight":-0.425}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.038223},{"month":2,"riseRate":0.5,"avgChangeRate":0.008648},{"month":3,"riseRate":0.125,"avgChangeRate":-0.189422},{"month":4,"riseRate":0.5,"avgChangeRate":0.076221},{"month":5,"riseRate":0.375,"avgChangeRate":-0.127354},{"month":6,"riseRate":0.75,"avgChangeRate":0.001907},{"month":7,"riseRate":0.625,"avgChangeRate":0.09173},{"month":8,"riseRate":0.375,"avgChangeRate":-0.034322},{"month":9,"riseRate":0.25,"avgChangeRate":-0.084616},{"month":10,"riseRate":0.555556,"avgChangeRate":0.008801},{"month":11,"riseRate":0.666667,"avgChangeRate":0.137505},{"month":12,"riseRate":0.5,"avgChangeRate":0.349087}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction